Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00225017 · ClinicalTrials.gov registry record · Phase 3
Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study
A Phase 3 study of HIV Infection and Hyperlipidemia, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 7
- Study locations
NCT00225017 is a Phase 3 study of HIV Infection and Hyperlipidemia that has completed, run by Northwestern University. The registered enrollment target is 50 participants, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (79% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT00225017, a Phase 3 study of HIV Infection and Hyperlipidemia, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to evaluate the change in brachial artery reactivity in HIV-infected subjects with elevated lipid levels who are switched to an atazanavir containing antiretroviral regimen
Conditions Studied
Interventions
- DRUG Atazanavir
- DRUG current antiretroviral regimen
Study Locations (7)
Other
- ACLIRES - Argentina S.R.L. - Buenos Aires
- Universita degli studi di Modena e Reggio Emilia - Modena
California
- University of California - San Diego
Illinois
- Northwestern Universtiy - Chicago
Indiana
- Indiana University - Indianapolis
Ohio
- University of Cincinnati - Cincinnati
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00225017
The ClinicalTrials.gov registry entry for NCT00225017 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (79% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infection appearing as the primary indexed condition, and to 2 interventions - of which Atazanavir is the first listed.
NCT00225017 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00225017 about?
NCT00225017 is a clinical study titled "Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study". The purpose of this study is to evaluate the change in brachial artery reactivity in HIV-infected subjects with elevated lipid levels who are switched to an atazanavir containing antiretroviral regimen
What is the current status of trial NCT00225017?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2005-06. Estimated completion is 2008-06.
What conditions does trial NCT00225017 study?
This clinical trial studies the following conditions: HIV Infection, Hyperlipidemia.
What interventions are being tested in trial NCT00225017?
The interventions under investigation include: Atazanavir (DRUG), current antiretroviral regimen (DRUG).
Who is sponsoring clinical trial NCT00225017?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00225017 being conducted?
This trial has 7 study locations across California, Illinois, Indiana, Ohio, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
ACTIVE NOT RECRUITING · Phase 3
-
Comparative Study of Three NNRTI-Sparing HAART Regimens
COMPLETED · Phase 3
-
A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy
COMPLETED · Phase 3
-
Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients
COMPLETED · Phase 3
-
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
COMPLETED · Phase 3
-
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.